William U. Shipley
#127,592
Most Influential Person Now
William U. Shipley's AcademicInfluence.com Rankings
William U. Shipleyphilosophy Degrees
Philosophy
#6043
World Rank
#9006
Historical Rank
Logic
#3234
World Rank
#4361
Historical Rank
William U. Shipleybiology Degrees
Biology
#8185
World Rank
#11223
Historical Rank
Biochemistry
#1171
World Rank
#1289
Historical Rank
Download Badge
Philosophy Biology
William U. Shipley's Degrees
- PhD Biochemistry Stanford University
- Doctorate Medicine Stanford University
Why Is William U. Shipley Influential?
(Suggest an Edit or Addition)William U. Shipley's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. (2006) (2358)
- Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. (2005) (1239)
- Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials (2000) (784)
- Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. (1997) (616)
- Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. (2003) (573)
- Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. (2010) (570)
- Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. (2008) (516)
- Radiotherapy and short-term androgen deprivation for localized prostate cancer. (2011) (495)
- Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. (1999) (463)
- Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer (2017) (449)
- Biology and management of bladder cancer. (1990) (418)
- Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. (1991) (413)
- Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. (1995) (406)
- Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of radiation therapy oncology group 89-03. (1998) (379)
- ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. (2013) (378)
- Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. (2012) (375)
- Bladder cancer (2009) (319)
- Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. (2002) (314)
- Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. (2014) (312)
- Radiation dose-volume effects of the urinary bladder. (2010) (302)
- Bladder cancer. Clinical practice guidelines in oncology. (2005) (278)
- Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. (2014) (272)
- Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. (2003) (270)
- Laparoscopy in the staging and planning of therapy for pancreatic cancer. (1986) (241)
- Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. (1994) (241)
- Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. (2019) (236)
- Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. (2002) (229)
- Bladder preservation by combined modality therapy for invasive bladder cancer. (1997) (223)
- Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. (1987) (223)
- Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. (2007) (222)
- Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. (2003) (222)
- The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. (2000) (213)
- Selective bladder preservation by combination treatment of invasive bladder cancer. (1993) (210)
- Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. (2013) (206)
- Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. (2008) (202)
- Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. (2003) (201)
- Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. (2017) (201)
- Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. (2009) (199)
- Bladder carcinoma as a systemic disease (1979) (197)
- Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. (2006) (192)
- Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. (2009) (189)
- RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. (2003) (188)
- PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. (2004) (183)
- Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. (1997) (182)
- Association of mammalian cell death with a specific endonucleolytic degradation of DNA (1974) (180)
- p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. (1997) (178)
- Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. (2009) (171)
- Intraoperative Electron Beam Irradiation for Patients with Unresectable Pancreatic Carcinoma (1981) (168)
- Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. (2000) (162)
- The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. (1995) (160)
- Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. (2004) (153)
- Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival. (1985) (151)
- The management of spermatic cord sarcoma (1996) (151)
- Late rectal bleeding following combined X-ray and proton high dose irradiation for patients with stages T3-T4 prostate carcinoma. (1993) (150)
- Proton radiation as boost therapy for localized prostatic carcinoma. (1979) (147)
- Penile cancer: Clinical Practice Guidelines in Oncology. (2013) (139)
- Nodal involvement as a prognostic indicator in patients with prostatic carcinoma. (1980) (133)
- Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. (2001) (131)
- Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. (2005) (129)
- Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with stages T1 and T2 tumor. (1994) (124)
- Residual, unresectable, or recurrent colorectal cancer: external beam irradiation and intraoperative electron beam boost +/- resection. (1983) (120)
- Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. (2018) (117)
- Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. (1996) (117)
- Treatment of malignant tumors of the spermatic cord: a study of 10 cases and a review of the literature. (1981) (116)
- A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). (2015) (114)
- Ki-67 Staining Index Predicts Distant Metastasis and Survival in Locally Advanced Prostate Cancer Treated With Radiotherapy (2004) (114)
- Overview of bladder cancer trials in the Radiation Therapy Oncology Group (2003) (114)
- Radiotherapy for bladder cancer. (2007) (113)
- Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. (2015) (112)
- Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. (2002) (112)
- Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. (2015) (112)
- Conformal irradiation of the prostate: estimating long-term rectal bleeding risk using dose-volume histograms. (1996) (109)
- Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. (2013) (109)
- Complications of intraoperative radiation therapy. (1984) (109)
- COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. (2007) (106)
- Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors. (2002) (105)
- Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. (2019) (103)
- Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications (1993) (103)
- Iodine‐125 implant and external beam irradiation in patients with localized pancreatic carcinoma. A comparative study to surgical resection (1980) (103)
- The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. (2010) (101)
- Influence of tumour size on hypoxic fraction and therapeutic sensitivity of Lewis lung tumour. (1977) (100)
- Megavoltage irradiation for pure testicular seminoma: Results and patterns of failure (1981) (100)
- Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. (1999) (94)
- Repair of radiation damage in Lewis lung carcinoma cells following in situ treatment with fast neutrons and gamma-rays. (1975) (93)
- Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. (2012) (93)
- Intraoperative irradiation for unresectable pancreatic carcinoma (1982) (93)
- Bcl-2 and Bax Expression Predict Prostate Cancer Outcome in Men Treated with Androgen Deprivation and Radiotherapy on Radiation Therapy Oncology Group Protocol 92-02 (2007) (88)
- Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: analysis of freedom from PSA failure. (1993) (87)
- Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. (2010) (86)
- Adenovirus‐mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo (2005) (86)
- Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy. (1991) (85)
- Patient‐reported outcomes after 3‐dimensional conformal, intensity‐modulated, or proton beam radiotherapy for localized prostate cancer (2013) (85)
- Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. (2009) (84)
- Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels. (1991) (83)
- Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. (2019) (83)
- A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. (1998) (82)
- Tumor size dependency in the radiation response of the Lewis lung carcinoma. (1975) (81)
- Invasive bladder cancer: tumor configuration, lymphatic invasion and survival. (1983) (78)
- Obesity and mortality in men with locally advanced prostate cancer (2007) (78)
- Radiation therapy for localized prostate carcinoma: experience at the Massachusetts General Hospital (1973-1981). (1988) (77)
- Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12. (2011) (77)
- Intraoperative irradiation: A pilot study combining external beam photons with “boost” dose intraoperative electrons (1982) (76)
- Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy. (1990) (74)
- An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy. (1999) (73)
- Renal complications secondary to radiation treatment of upper abdominal malignancies. (1986) (72)
- Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. (2005) (70)
- Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. (2008) (68)
- The value of CT scanning in radiation therapy treatment planning: a prospective study. (1979) (68)
- Cisplatin and full dose irradiation for patients with invasive bladder carcinoma: a preliminary report of tolerance and local response. (1984) (67)
- Invasive bladder carcinoma. The importance of initial transurethral surgery and other significant prognostic factors for improved survival with full‐dose irradiation (1987) (67)
- Bladder cancer. (2013) (67)
- Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. (2014) (65)
- Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results. (1997) (64)
- Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10. (2003) (63)
- Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. (2018) (62)
- The role of misonidazole combined with intraoperative radiation therapy in the treatment of pancreatic carcinoma. (1987) (62)
- Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. (2019) (62)
- Spermatic cord sarcomas: Sonographic and CT features (1990) (61)
- Protons or megavoltage X‐rays as boost therapy for patients irradiated for localized prostatic carcinoma an early phase I/II comparison (1983) (60)
- Intraoperative +/- external beam irradiation. (1983) (60)
- Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation. (1994) (59)
- Trimodality bladder preservation therapy for muscle-invasive bladder cancer. (2013) (59)
- Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. (2002) (58)
- Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy. (2017) (58)
- Dose inhomogeneity in interstitial implants using 125I seeds. (1979) (58)
- Biochemical and clinical significance of the posttreatment prostate‐specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone (2006) (57)
- A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. (2015) (56)
- Low‐dose preoperative irradiation, surgery, and elective postoperative radiation therapy for resectable rectum and rectosigmoid carcinoma (1983) (55)
- Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy. (2001) (54)
- The effect of pelvic radiation therapy on serum levels of prostate specific antigen. (1994) (54)
- Bladder cancer. The selection of patients for treatment by full‐dose irradiation (1985) (53)
- Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. (2007) (53)
- NCCN Urothelial Cancer Practice Guidelines (1998) (52)
- Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. (2008) (51)
- Survivin is a potential mediator of prostate cancer metastasis. (2010) (51)
- Invasive bladder cancer: treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation. (1997) (51)
- Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10. (2006) (50)
- Preoperative irradiation, lymphadenectomy, and 125iodine implantation for patients with localized carcinoma of the prostate. (1986) (48)
- Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer (2021) (48)
- Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92-02. (2006) (48)
- Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. (2020) (46)
- Bladder preservation: optimizing radiotherapy and integrated treatment strategies (2008) (45)
- Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup. (1994) (45)
- PSA bounces after neoadjuvant androgen deprivation and external beam radiation: impact on definitions of failure. (2005) (44)
- The combination of cis-platin based chemotherapy and radiation in the treatment of muscle-invading transitional cell cancer of the bladder. (1993) (44)
- Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all? (2003) (44)
- Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease. (1996) (43)
- Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. (2012) (42)
- Quality control parameters of intraoperative radiation therapy. (1986) (41)
- Reduction of the scatter dose to the testicle outside the radiation treatment fields. (1982) (41)
- Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610. (2003) (41)
- Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06. (2011) (39)
- Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233. (2014) (39)
- Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial. (2010) (39)
- 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. (2004) (38)
- Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer. (2011) (37)
- SIU–ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer (2019) (37)
- A randomized trial comparing conventional dose (70.2GyE) and high-dose (79.2GyE) conformal radiation in early stage adenocarcinoma of the prostate: Results of an interim analysis of PROG 95–09 (2004) (37)
- Management of spinal cord compression secondary to metastatic prostatic carcinoma. (1991) (36)
- A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524). (2017) (36)
- Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. (2009) (35)
- Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: Results from the National Cancer Data Base. (2017) (35)
- Immune cytolysis in relation to the growth cycle of Chinese hamster cells. (1971) (34)
- Long-term quality of life outcome after proton beam monotherapy for localized prostate cancer. (2012) (34)
- Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer (2018) (34)
- Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. (2020) (33)
- Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma. (2012) (33)
- Invasive bladder carcinoma: preliminary report of selective bladder conservation by transurethral surgery, upfront MCV (methotrexate, cisplatin, and vinblastine) chemotherapy and pelvic irradiation plus cisplatin. (1988) (33)
- Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610. (2005) (33)
- Organ-conserving approaches to muscle-invasive bladder cancer: future alternatives to radical cystectomy (2000) (32)
- Comparative Effectiveness of Bladder‐preserving Tri‐modality Therapy Versus Radical Cystectomy for Muscle‐invasive Bladder Cancer (2019) (32)
- Thymosin beta-15 predicts for distant failure in patients with clinically localized prostate cancer-results from a pilot study. (2000) (32)
- Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder (2004) (32)
- Potentiation of x-ray killing by 5-bromodeoxyuridine in Chinese hamster cells: a reduction in capacity for sublethal damage accumulation. (1971) (31)
- Defining recurrence after radiation for prostate cancer. (2005) (31)
- NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. (1998) (30)
- Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer. (2013) (30)
- Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk. (2012) (30)
- Bladder cancer. Clinical guidelines in oncology. (2006) (30)
- Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases. (2013) (30)
- Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408. (2015) (30)
- [Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials]. (2001) (28)
- Deoxyribonucleic acid flow cytometry in invasive bladder carcinoma: a possible predictor for successful bladder preservation following transurethral surgery and chemotherapy-radiotherapy. (1992) (28)
- Pure seminoma of the testis: the results of radiation therapy in patients with elevated human chorionic gonadotropin titers. (1985) (27)
- Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA (2016) (26)
- Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival. (2013) (26)
- Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. (2014) (26)
- The Importance of Protein Kinase A in Prostate Cancer: Relationship to Patient Outcome in Radiation Therapy Oncology Group Trial 92-02 (2009) (26)
- Carcinoma of the female urethra: a review of results with radiation therapy. (1988) (25)
- Cisplatin as adjunctive treatment for invasive bladder carcinoma: tolerance and toxicities. (1984) (25)
- Flow cytometric analysis of DNA ploidy, percent S-phase fraction, and total proliferative fraction as prognostic indicators of local control and survival following radiation therapy for prostate carcinoma. (1994) (25)
- The demonstration in the domestic guinea pig of a process resembling classical imprinting (1963) (25)
- 4,000 RAD preoperative irradiation followed by prompt radical cystectomy for invasive bladder carcinoma: a prospective study of patient tolerance and pathologic downstaging. (1982) (24)
- Testicular seminoma: clinical and pathological features that may predict para-aortic lymph node metastases. (1990) (24)
- The use of local allograft irradiation following renal transplantation. (1984) (24)
- Influence of follow-up bias on PSA failure after external beam radiotherapy for localized prostate cancer: results from a 10-year cohort analysis. (2003) (24)
- Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. (2006) (23)
- Intraoperative radiation therapy. (1986) (23)
- Short-term Endocrine Therapy Prior to and during Radiation Therapy Improves Overall Survival in Patients with T1b-T2b Adenocarcinoma of the Prostate and PSA ≤ 20: Initial Results of RTOG 94-08 (2010) (22)
- Preoperative irradiation, lymphadenectomy and 125iodine implant for patients with localized prostatic carcinoma: a correlation of implant dosimetry with clinical results. (1980) (22)
- The results of concurrent chemo‐radiotherapy for recurrence after treatment with bacillus Calmette‐Guérin for non‐muscle‐invasive bladder cancer: is immediate cystectomy always necessary? (2009) (21)
- Bladder cancer.Advances in laboratory innovations and clinical management, with emphasis on innovations allowing bladder‐sparing approaches for patients with invasive tumors (1990) (21)
- An Update of Selective Bladder Preservation by Combined Modality Therapy for Invasive Bladder Cancer (1998) (20)
- Bladder-sparing approaches to invasive disease (2006) (20)
- Radiation-based approaches to the management of T3 prostate cancer. (1997) (20)
- Enhanced tumor cell radiosensitivity in artificial pulmonary metastases of the Lewis lung carcinoma. (1976) (20)
- Muscle-invading bladder cancer, RTOG Protocol 99-06: Initial report of a phase I/II trial of selective bladder-conservation employing TURBT, accelerated irradiation sensitized with cisplatin and paclitaxel followed by adjuvant cisplatin and gemcitabine chemotherapy (2005) (20)
- Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer. (2006) (20)
- Combined modality treatment with selective bladder conservation for invasive bladder cancer: long-term tolerance in the female patient. (1996) (20)
- Current concepts in the management of patients with deeply invasive bladder carcinoma. (1979) (19)
- Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy. (1997) (19)
- A beam width improving device for a 25 MV X ray beam. (1986) (19)
- Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience. (2017) (19)
- Can chemo-radiotherapy plus transurethral tumor resection make cystectomy unnecessary for invasive bladder cancer? (1990) (18)
- Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial. (2007) (18)
- Long-term durability of PSA failure-free survival after radiotherapy for localized prostate cancer. (2002) (18)
- Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. (2016) (18)
- 22: Ten Year Follow-up of RTOG 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer (2006) (18)
- The long-term effect on PSA values of incidental prostatic irradiation in patients with pelvic malignancies other than prostate cancer. (1999) (17)
- Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: An analysis of RTOG 94-08. (2012) (17)
- Management of carcinoma of the bladder. (1998) (17)
- DNA damage and repair following irradiation: the effect of 5-bromodeoxyuridine in cultured Chinese hamster cells. (1971) (17)
- Conservative surgery, patient selection, and chemoradiation as organ-preserving treatment for muscle-invading bladder cancer. (1996) (17)
- Benchmarks achieved in the delivery of radiation therapy for muscle-invasive bladder cancer. (2007) (17)
- Radiotherapy and chemotherapy in invasive bladder cancer with potential bladder sparing. (1992) (16)
- Organ-sparing treatment for bladder cancer: time to beat the drum. (1994) (16)
- Newer imaging modalities to assist with target localization in the radiation treatment of prostate cancer and possible lymph node metastases. (2008) (16)
- THE STATUS OF BLADDER‐PRESERVING THERAPEUTIC STRATEGIES IN THE MANAGEMENT OF PATIENTS WITH MUSCLE‐INVASIVE BLADDER CANCER (1995) (16)
- Trimodality Therapy for Bladder Conservation in Treatment of Invasive Bladder Cancer (2013) (16)
- Continuous irradiation of the Lewis lung carcinoma in vivo at clinically-used "ultra" low-dose-rates. (1983) (15)
- Two Years of Anti-Androgen Treatment Increases Other-Cause Mortality in Men Receiving Early Salvage Radiotherapy: A Secondary Analysis of the NRG Oncology/RTOG 9601 Randomized Phase III Trial (2019) (15)
- DNA degradation in mammalian cells following complement-mediated cytolysis. (1971) (15)
- Clinical experience with proton beam radiation therapy. (1980) (15)
- Radiation therapy of Hodgkin's disease: Significance of splenic involvement (1974) (14)
- Phase III trial of hormonal cytoreduction in conjunction with definitive radiotherapy in locally advanced prostate carcinoma: the emerging role of psa in the assessment of outcome (1993) (14)
- Androgen Receptor Activity and Radiotherapeutic Sensitivity in African-American Men with Prostate Cancer: A Large Scale Gene Expression Analysis and Meta-Analysis of RTOG Trials (2018) (14)
- Contemporary Patterns of Multidisciplinary Care in Patients With Muscle‐invasive Bladder Cancer (2018) (14)
- Nodal involvement as prognostic indicator in prostatic carcinoma. (1981) (13)
- Role of lymphangiography in stagingtesticular seminoma (1991) (13)
- Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer: An analysis of RTOG 94-08. (2011) (13)
- Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01. (2016) (12)
- Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413. (2008) (12)
- Bladder cancer. (2009) (12)
- Future prospects of radiation therapy with protons. (1981) (12)
- Intraoperative radiation therapy in patients with bladder cancer. A review of techniques allowing improved tumor doses and providing high cure rates without loss of bladder function (1987) (12)
- MicroRNA Biomarkers for Patients With Muscle-Invasive Bladder Cancer Undergoing Selective Bladder-Sparing Trimodality Treatment. (2019) (12)
- The advantage of an X-ray visible marker of the prostatic apex. (1993) (12)
- NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA. (2016) (12)
- 1016 Biochemical outcome following external beain radiation therapy for T1–2 prostate carcinoma: the importance of achieving an undetectable nadir PSA (1995) (11)
- Full-dose irradiation for invasive bladder cancer: prognostic factors and techniques. (1984) (11)
- The biochemical and clinical significance of the post-treatment PSA bounce for prostate cancer patients treated with external beam radiation therapy alone: A multi-institutional pooled analysis (2004) (11)
- Interval report of a phase I-II study utilizing multiple modalities in the treatment of invasive bladder cancer. A bladder-sparing trial. (1991) (11)
- Bladder cancer. The selection of patients for treatment by full-dose irradiation. (1985) (11)
- The role of radiation therapy and chemotherapy in the treatment of invasive carcinoma of the urinary bladder. (1988) (10)
- The success of radiation therapy in controlling prostatic cancer within the treated field. (1987) (10)
- The impact of MRE11 in nuclear to cytoplasmic ratio on outcomes in muscle invasive bladder cancer an analysis of NRG/RTOG 8802, 8903, 9506, 9706, 9906, and 0233. (2017) (10)
- A strategy against pancreatic cancer. (1982) (10)
- The initial report of RTOG 0524: Phase I/II trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation following transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer. (2014) (10)
- RTOG 9706: initial report of a phase I/II trial of bladder-conservation employing TURB, accelerated irradiation sensitized with Cisplatin followed by adjuvant MCV chemotherapy (2001) (10)
- Outcomes of Selective Bladder Preservation in the Elderly Treated With Conservative Surgery and Chemoradiation (2013) (10)
- Prolonged "ultra" low-dose-rate irradiation: effects on Chinese hamster cell population growth, survival, and radiation sensitivity. (1981) (10)
- 42 A phase trial of transurethral surgery plus cisplatin and radiation therapy followed by either selective bladder preservation or radical cystectomy for patients with muscle-invading bladder cancer but without hydronephrosis (1997) (10)
- 97 A randomized trial comparing local tumor control following irradiation alone versus combined androgen withdrawal and irradiation in an androgen sensitive prostate cancer xenograft (1995) (9)
- Cisplatin and external beam radiation in patients with invasive bladder cancer. (1989) (9)
- Proton Beam Therapy in Localized Prostate Cancer (2000) (9)
- Bladder preservation strategies. (2015) (9)
- An organ-preserving approach to muscle-invading transitional cell cancer of the bladder. (2001) (9)
- A Prospective Phase I/II Study using Proton Beam Radiation to Deliver 82GyE to Men with Localized Prostate Cancer: Preliminary Results of ACR 0312 (2008) (8)
- Intraoperative irradiation: A pilot study combining external beam with “boost” dose intraoperative electrons (1979) (8)
- PROSPECTIVE STUDY OF THE VALUE OF CT SCANNING IN RADIATION THERAPY TREATMENT PLANNING (1977) (8)
- Treatment strategies using transurethral surgery, chemotherapy, and radiation therapy with selection that safely allows bladder conservation for invasive bladder cancer. (1997) (8)
- Urological cancer: The benefits of intermittent androgen-deprivation therapy (2012) (8)
- Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233. (2012) (8)
- Old drugs, new purpose--bladder cancer turning a corner. (2012) (8)
- 41 : A Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy (1997) (8)
- Does neoadjuvant hormone treatment compromise subsequent androgen suppression in prostate cancer patients who fail initial radiation therapy: a secondary analysis of RTOG 86-10 (2000) (8)
- Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields. (2013) (8)
- The integration of chemotherapy, radiotherapy and transurethral surgery in bladder-sparing approaches for patients with invasive tumors. (1990) (7)
- Radiation therapy for testicular seminoma: controversies in the management of early-stage disease. (1992) (7)
- Reduction of the Scatter Dose to the Testicle Outside the Radiation Treatment Fields (1983) (7)
- Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial. (2020) (7)
- Mapping patterns of nodal metastases in seminoma: Rethinking radiotherapy fields. (2012) (7)
- Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy. (2021) (7)
- Ki-67 staining is a strong predictor of patient outcome for prostate cancer patients treated with androgen deprivation plus radiotherapy: an analysis of RTOG 92–02 (2003) (7)
- Intraoperative radiation therapy for patients with pancreatic carcinoma (1984) (7)
- Preliminary Results of RTOG 0233: A Phase II Randomized Trial for Muscle-invading Bladder Cancer Treated by Transurethral Resection and Radiotherapy Comparing Two Forms of Concurrent Induction Chemotherapy (2010) (7)
- Bowenoid papulosis: a benign lesion of the shaft of the penis misdiagnosed as squamous carcinoma. (1997) (7)
- Multi-institutional matched comparison of radical cystectomy to trimodality therapy for muscle-invasive bladder cancer. (2022) (6)
- Opportunities with combined modality therapy for selective organ preservation in muscle‐invasive bladder cancer (1996) (6)
- 308: An Update of Selective Bladder Preservation Using Combined Modality Treatment in Invasive Bladder Cancer: Long Term Outcome Reveals a Low Risk of Invasive Recurrence and a High Probability of Bladder Preservation (2004) (6)
- Cardiovascular Mortality Following Androgen Deprivation Therapy in Men With Locally Advanced Prostate Cancer: An Analysis of RTOG 85-31 (2007) (6)
- Progress in the management of T3-4 adenocarcinoma of the prostate. (1997) (6)
- Validation of a 22-gene Genomic Classifier in the NRG Oncology/RTOG 9202, 9413 and 9902 Phase III Randomized Trials: A Biopsy-Based Individual Patient Meta-Analysis in High-Risk Prostate Cancer. (2021) (6)
- Guidelines for radiation therapy in clinical research on bladder cancer. (1986) (6)
- Results of a randomized trial of total radiation for stage T3-T4 prostate cancer boosting with photons (to 67.2 cge) or with conformal protons (to 75.6 CGE) (1994) (6)
- Predicting survival and the role of androgen suppressive therapy (AST): Radiation therapy oncology group (RTOG) phase III randomized prostate cancer trials (1998) (6)
- Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long‐term Results of a Single‐institution Experience (2017) (6)
- Adjuvant radiation therapy for pathologic T3 prostate cancer (1993) (6)
- Immune cytolysis and x irradiation: independent lethal action in Chinese hamster cells in vitro. (1972) (5)
- Long-term quality of life after conventional-dose versus high-dose radiation for prostate cancer: Results from a randomized trial (PROG 95–09) (2008) (5)
- 1141 Selective bladder preservation by combined modality therapy for invasive bladder cancer (1995) (5)
- Radiation as adjunctive therapy to cystectomy for bladder cancer. (1993) (5)
- The durability of PSA failure-free survival from 5 years to 13 years following radiotherapy in patients with localized prostate cancer (2000) (5)
- Adriamycin sensitivity following "ultra" low dose rate irradiation of Lewis lung carcinoma in vivo. (1985) (5)
- Radiation Therapy Oncology Group (RTOG) 9413: Randomized trial comparing whole pelvic radiotherapy (WPRT) to prostate only (PORT) and neoadjuvant hormone therapy (NHT) to adjuvant hormone therapy (AHT). (2013) (5)
- The role of radiation therapy in the treatment of testicular germ cell tumors. (1991) (5)
- Selective bladder preservation by combined modality treatment of invasive bladder cancer: 10-Year outcome (2001) (5)
- The Impact of MRE11 in Nuclear to Cytoplasmic Ratio on Outcomes in Muscle Invasive Bladder Cancer: an Analysis of NRG/RTOG 8802, 8903, 9506, 9706, 9906, and 0233. (2017) (5)
- Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: A pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233. (2012) (5)
- The role of radiotherapy in patients with advanced seminomatous germ cell tumors. Controversies in management. Part 2. (1992) (5)
- Cisplatin and Full-Dose Irradiation for Patients with Invasive Bladder Carcinoma: The National Bladder Cancer Group Experience (1987) (5)
- Adding short-term androgen deprivation therapy to RT in men with localized prostate cancer: long-term update of the NRG/RTOG 9408 randomized clinical trial. (2021) (5)
- The value of external beam radiation in node positive prostate cancer (2001) (5)
- 2018 Selective bladder preservation by combined modality therapy for invasive bladder cancer (1995) (5)
- Does Adjuvant Hormonal Therapy Improve Freedom From Biochemical Relapse in Prostate Cancer Patients Receiving Dose-Escalated Radiation Therapy? An Analysis of RTOG 94-06 (2007) (5)
- Editorial: Radical Treatment With Radiation of “Early Stage” Prostate Cancer: Impressive Results With Long-Term Followup (1994) (4)
- PSA following irradiation for prostate cancer: the upcoming ASTRO symposium. (1996) (4)
- Long-Term Update of NRG Oncology RTOG 94-08 (2018) (4)
- Inflammatory metastatic breast cancer with gallbladder metastasis: an incidental finding. (2015) (4)
- Immunosuppressive agents and immune cytolysis in vitro: the effect of azathioprine, hydrocortisone, and radiation of antiserum- and complement-mediated lysis of cultured mammalian cells. (1972) (4)
- Late rectal bleeding following 75.6 CGE by proton radiation as boost therapy to stage T3–4 prostate cancer irradiated on a phase III trial: The significance, in the anterior rectum, of both fractional volume treated and total dose received (1992) (4)
- Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601 (2022) (4)
- Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: Associations with clinical variables and survival. (2013) (4)
- Radio-chemotherapy for invasive carcinoma of the bladder. (1992) (4)
- Surrogate endpoint for prostate cancer-specific survival: Validation from an analysis of Radiation Therapy Oncology Group Protocol 92–02 (2005) (4)
- The role of neoadjuvant or adjuvant chemotherapy for invasive bladder cancer Is there a benefit for survival or preserving the bladder? (1998) (4)
- The Influence of Age as a Predictor of Outcome in Prostate Cancer Patients Treated on RTOG Trials (2007) (4)
- Response to continuous irradiation (CI) in relation to the initial slope of the cell survival curve for tumours and bone marrow. (1984) (4)
- NRG Oncology/RTOG 0926: Phase II Protocol for Patients With Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging. (2021) (4)
- Acute and Late Urinary Toxicity After Radiation Therapy in Men With and Without an Intact Prostate Gland: A Secondary Analysis of RTOG 9408 and 9601 Suggesting This Toxicity is Not Due to Bladder Injury (2012) (4)
- Trimodality therapy in the management of muscle-invasive bladder cancer: a selective organ-preserving approach (2008) (4)
- Long-term outcome for men with prostate cancer treated with radiation as solo therapy (1994) (4)
- THE VALUE OF CT IN RADIOTHERAPY TREATMENT PLANNING (1978) (4)
- Radiation Therapy Oncology Group (RTOG) 9413: Randomized trial comparing whole pelvic radiotherapy (WPRT) to prostate only (PORT) and neoadjuvant hormone therapy (NHT) to adjuvant hormone therapy (AHT). (2012) (4)
- Invasive bladder cancer: MCV (methotrexate, cisplatin, vinblastine) followed by cisplatin plus pelvic irradiation and possible cystectomy: Patient tolerance and local tumor response (1987) (4)
- Impact of biochemical failure classification on clinical outcome: A secondary analysis of Radiation Therapy Oncology Group 9202 and 9413 (2015) (3)
- A Phase III Trial Employing Conformal Photons with Proton Boost in Early-stage Prostate Cancer: Conventional Dose (70.2 GyE) Compared to High-dose Irradiation (79.2 GyE): Long-term Updated Analysis of Proton Radiation Oncology Group (PROG)/American College of Radiology (ACR) 95–09 (2009) (3)
- Late Pelvic Toxicity Following Bladder-Sparing Therapy in Patients With Invasive Bladder Cancer: Analysis of RTOG 89-03, 95-06, 97-06, 99-06 (2007) (3)
- Prostatectomy or watchful waiting in prostate cancer. (2003) (3)
- Long-term Outcomes After Bladder-Preserving Combined Modality Therapy for Patients With Muscle-Invasive Bladder Cancer (2015) (3)
- Predicting outcome after PSA failure in prostate cancer patients treated by radiation. Who needs salvage therapy (2004) (3)
- Genomic profiling of muscle invasive bladder cancer to predict response to bladder-sparing trimodality therapy. (2018) (3)
- Organ conservation as an alternative to radical cystectomy for invasive bladder cancer: urodynamic and quality of life evaluation of patients treated by trimodality therapy (2002) (3)
- Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: Meta-analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 phase III randomized trials. (2022) (3)
- Surgery: Selective bladder-preserving therapy for muscle-invasive cancer (2009) (3)
- BIOLOGY AND MANAGEMENT OF BLADDER CANCER. REPLY (1991) (3)
- A progress report on the results of multimodality therapy for muscle-invasive bladder cancer. (1990) (3)
- The case for radiotherapy with or without chemotherapy in high-risk superficial and muscle-invading bladder cancer. (1997) (3)
- Long-term outcomes among patients who achieve complete or near-complete responses after the induction phase of bladder-preserving combined modality therapy for muscle-invasive bladder cancer: A pooled analysis of RTOG 9906 and 0233. (2014) (3)
- Words of wisdom. Re: Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. (2013) (3)
- Clinical outcomes and prognostic factors in 4839 patients treated with external radiotherapy for stage T1-T2 prostate cancer (2004) (3)
- 141 Overall survival and local control following combined modality therapy and selective bladder preservation for invasive bladder cancer (1996) (3)
- Receipt of aggressive therapies for muscle-invasive bladder cancer: Results from the National Cancer Data Base. (2012) (3)
- A three-dimensional ct based analysis of inter-fraction bladder motion during radiotherapeutic treatment of bladder cancer (2004) (3)
- Review of factors predicting improved tumor control and survival from invasive bladder carcinoma following external beam radiation therapy. (1988) (3)
- Hormonal therapies: ADT for prostate cancer: true love or heartbreak? (2010) (3)
- Post-irradiation biopsy of the prostate in stage T3 prostatc cancer: Correlation with original histologic grade and with current PSA values (1990) (3)
- The Long-Term Success of Local Radiation Therapy in Preventing Tumor Regrowth in the Treated Field (1988) (3)
- Early stage testicular seminoma: the role of radiation therapy following orchiectomy. (1994) (2)
- 65 : Temporal Profile of Serum Testosterone With Goserelin Use and Cessation: Analysis of Radiation Therapy Oncology Group Protocol 92-02 (2006) (2)
- Bowel and bladder toxicity patterns in patients with prostate cancer treated with proton beam versus intensity-modulated radiation therapy. (2012) (2)
- Exploring multidisciplinary practice patterns in the management of muscle invasive bladder cancer (MIBC) across the U.S. and Canada in 2015. (2016) (2)
- Recent advances and the emerging role for chemoradiation in nonmuscle invasive bladder cancer (2013) (2)
- RADIATION THERAPY ONCOLOGY GROUP RTOG 0926 A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1 BLADDER CANCER TO EVALUATE SELECTIVE BLADDER PRESERVING TREATMENT BY RADIATION THERAPY CONCURRENT WITH RADIOSENSITIZING CHEMOTHERAPY FOLLOWING A THOROUGH TRANSURETHRAL SURGICAL RE-STAGING (2012) (2)
- Outcomes and Tolerability of Selective Bladder Preservation by Combined Modality Therapy for Invasive Bladder Cancer in Elderly Patients (2017) (2)
- The importance of combined radiation and endocrine therapy in locally advanced prostate cancer. (2012) (2)
- Evaluation of significant late morbidity from external beam irradiation for adenocarcinoma of the prostate (Analysis from RTOG Studies 7506 and 7706) (1990) (2)
- 1013 Time to second prostate specific antigen (PSA) failure is a surrogate endpoint for prostate cancer death in prospective trials of therapy for localized disease (1995) (2)
- Selective Bladder Preservation with Twice-Daily Radiation Plus 5-Flourouracil/Cisplatin or Daily Radiation Plus Gemcitabine for Patients with Muscle Invasive Bladder Cancer—Primary Results of NRG/RTOG 0712: A Randomized Phase 2 Multicenter Trial (2017) (2)
- Iodine-125 implant and external beam irradiation in patients with localized pancreatic carcinoma. [Efficacy and complications] (1980) (2)
- Spermatic cord sarcoma: The role of adjuvant external beam irradiation (1994) (2)
- Early salvage versus adjuvant post-prostatectomy radiation therapy: Long-term results of a large institutional experience. (2016) (2)
- The Prognostic Value of p16 Expression in Locally Advanced Prostate Cancer: A Study Based on RTOG 92-02 (2005) (2)
- Comparative effectiveness of bladder-preserving tri-modality therapy versus radical cystectomy for muscle-invasive bladder cancer. (2018) (2)
- 203 Bladder cancer: The combination of chemotherapy and irradiation in the treatment of patients with muscle-invading tumors (1993) (2)
- 2321: Treatment of Prostate Cancer With Photon IMRT and Proton Therapy: a Treatment Planning Comparison (2006) (2)
- Chapter 52 – Bladder Cancer (2012) (2)
- Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 3-2004. A 57-year-old man with invasive transitional-cell carcinoma of the bladder. (2004) (2)
- Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee. (2001) (2)
- Translational research in bladder cancer. (1996) (2)
- PSA failure free survival following irradiation for stage T1–T2 prostate cancer patients: The results of an ASTRO sponsored pooled analysis (1998) (2)
- An assessment of the in vitro radiosensitivity of a human prostate cancer cell line: The influence of the hormonal millieu (1994) (2)
- Quality of life assessment in women after combined modality treatment with bladder conservation for invasive bladder cancer (1994) (2)
- Thoughtful, practical and timely radiation therapy guidelines for patients with muscle‐invasive bladder cancer (2012) (1)
- Adjuvant Radiation Therapy for Early Stage Seminoma: A Proton-photon Treatment Planning Comparison (2010) (1)
- Radiation therapy. (1992) (1)
- Abstract1123: Bcl-2 and Bax Predict Prostate Cancer Outcome in Men Treated With Androgen Deprivation and Radiotherapy on RTOG 92-02 (2006) (1)
- VEGF-D Expression Predicts Biochemical Outcome in Localized Prostate Cancer Treated with External Radiation: A Ten Year Cohort Analysis (2005) (1)
- Receipt of aggressive therapies for muscle-invasive bladder cancer: Results from the National Cancer Data Base. (2012) (1)
- Individual Patient Data Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium: Impact of Androgen Deprivation Therapy Use and Duration With Definitive Radiotherapy for Localized Prostate Cancer. (2021) (1)
- In Reply to Ms. Albertini et al. (2007) (1)
- Adjuvant radiation therapy for early-stage seminoma: Proton-photon comparison and second cancer risk. (2011) (1)
- MP26-12 INCIDENCE AND MANAGEMENT OF NON-MUSCLE INVASIVE BLADDER CANCER RECURRENCES AFTER COMPLETE RESPONSE TO COMBINED-MODALITY ORGAN-PRESERVING THERAPY FOR MUSCLE-INVASIVE BLADDER CANCER (2015) (1)
- Subtyping muscle-invasive bladder cancer to assess clinical response to trimodality therapy. (2017) (1)
- The Role of Radiation Therapy and Chemotherapy in the Treatment of Invasive Carcinoma of the Urinary Bladder (1989) (1)
- Combined modality therapy for the treatment of invasive bladder cancer (1991) (1)
- PSA Response after Short-term Hormonal Therapy Plus External Beam Radiotherapy and Outcome in Patients Treated on RTOG 9413 (2010) (1)
- Prognostic risk group stratification for clinical and biochemical failure after external beam radiation of localized prostate cancer (2004) (1)
- Utilization of Potentially Curative Therapies for Muscle Invasive Bladder Cancer: Results From the National Cancer Data Base (2012) (1)
- Definitions of biochemical failure that best predict clinical failure in prostate cancer patients treated with external beam radiation alone- a multi-institutional pooled analysis (2003) (1)
- T1 high-grade bladder cancer recurring after BCG therapy: a curative alternative to radical cystectomy exists. Con. (2013) (1)
- UROLOGIC ONCOLOGY: PROSTATE CANCER Failure Definition-Dependent Differences in Outcome Following Radiation for Localized Pros- tate Cancer: Can One Size Fit All? (2005) (1)
- The Initial Report of RTOG 0524: Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer (2014) (1)
- 1124 : Cox-2 Overexpression Predicts Prostate Cancer Outcome: An Analysis of RTOG 92-02 (2006) (1)
- Organ preservation approaches with radiation therapy in muscle-invasive bladder carcinoma. (1996) (1)
- The treatment of patients with testicular tumors (1979) (1)
- Bladder Preservation with Twice-Daily Radiation plus 5-Flourouracil/Cisplatin or Daily Radiation plus Gemcitabine for MIBC – Updated Results of NRG/RTOG 0712: A Randomized Phase 2 Trial (2020) (1)
- Genitourinary cancer committee (2001) (1)
- Long-term Outcomes After Bladder Preserving Combined Modality Therapy for Muscle-invasive Bladder Cancer: A Pooled Analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233 (2012) (1)
- Optimizing full-dose radiation therapy in the successful bladder-sparing management of patients with invasive bladder carcinoma (1988) (1)
- Salvage radiation therapy after radical prostatectomy for prostate adenocarcinoma: Analysis of biochemical control and prognostic factors (2000) (1)
- Mutational Landscape and Genetic Determinants of Response to Trimodality Therapy in Muscle-Invasive Bladder Cancer (2020) (1)
- Preoperative radiation, lymphadenectomy and iodine-125 implant for selected patients with localized prostatic carcinoma: A correlation of implant dosimetry with clinical results (1979) (1)
- Protons vs megavoltage xrays as boost therapy for patients with localized prostatic carcinoma (1980) (1)
- 4000 RAD preoperative irradiation followed by prompt radical cystectomy for invasive bladder carcinoma: A prospective study of patient tolerance and pathologic-down staging (1980) (1)
- 2196: Comparison of Two Types of Biochemical Failures Within the ASTRO and Phoenix Consensus Definitions in Patients Treated on RTOG 92–02 and 94–13 (2006) (1)
- Short-term adjuvant versus neoadjuvant hormone therapy in localized prostate cancer: A pooled individual patient analysis of two phase III trials. (2020) (1)
- Organ-sparing treatment of bladder cancer: an innovative approach. (1997) (1)
- Metastasis-Free Survival, but Not Biochemical Failure, is a Strong Surrogate Endpoint for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601 (2020) (1)
- Radiochemotherapy for invasive carcinoma of the bladder. (1993) (1)
- Fifteen-year Outcomes of Selective Bladder Preservation by Combined Modality Therapy for Invasive Bladder Cancer: The Long-term MGH Experience (2009) (1)
- Combined modality therapy as a means of blandder preservation for invasive bladder cancer (1998) (1)
- VEGF-D expression predicts biochemical outcome in localized prostate cancer treated with external radiation: A ten-year cohort analysis (2005) (1)
- Potential location of a bladder tumor suppressor gene on chromosome 9q at 9q13 to 9q22.1. (1995) (1)
- 1055 Prostate cancer: Estimating long-term rectal bleeding risk using dose-volume histograms (1995) (1)
- Radiation therapy for ureteral metastases from breast carcinoma (1981) (1)
- 145 Initial results of RTOG 95-06: A phase I/II trial of transurethral surgery and fractionated twice-daily radiation with concurrent cisplatin and 5-fluorouracil followed either by selective bladder preservation or cystectomy for patients with muscle-invading bladder cancer (1999) (0)
- Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-Term Results of a Large Institutional Experience (2016) (0)
- Pure seminoma of the testis: a review of a 26 year experience with megavoltage irradiation (1979) (0)
- The opportunity cost of androgen suppression in locally advanced prostate cancer. (2013) (0)
- Radical treatment with radiation of "early stage" prostate cancer: impressive results with long-term followup. (1994) (0)
- Two gonadal shielding devices that together markedly reduce the scattered radiation dose to the testis (1981) (0)
- Body mass index and mortality in men treated for locally advanced prostate cancer: An analysis of RTOG 85–31 (2007) (0)
- A Population-Based Treatment Margin for Respiratory Motion of Lung Tumors (2013) (0)
- In response to Drs. Kataria Sethi, Negi, and Rawat (2003) (0)
- Novel Predictive MicroRNA Signature in the Setting of Selective Trimodality Bladder Preservation Therapy (2014) (0)
- Celebrating 40 years of clinical inquiry: The RTOG'S ruby anniversary. (2008) (0)
- 1004 The value of external beam radiation in pathologic node positive prostate cancer: A multivariate analysis (1997) (0)
- Intraoperative electron-beam therapy and other bladder-sparing approaches to bladder carcinoma. (1988) (0)
- Proton radiation therapy of patients with prostatic carcinoma (1977) (0)
- The prognostic utility of hemoglobin and lymphocytopenia in bladder-sparing therapy. (2017) (0)
- Pretreatment PSA is a powerful independent predictor of outcome following treatment of prostate carcinoma by radical radiotherapy (1993) (0)
- Risk factors for disease progression after post-prostatectomy salvage radiation: Long-term results of a large institutional experience. (2016) (0)
- Protein Kinase A RI-α Overexpression is Associated with Prostate Cancer Outcome in Men Treated with Androgen Deprivation and Radiotherapy: A Secondary Analysis of RTOG 92-02 (2008) (0)
- Surrogate Endpoints for Prostate Cancer Survival: A Secondary Analysis of RTOG 9202 (2007) (0)
- Commentary (Shipley): Organ Preservation in Muscle-Invasive Bladder Cancer (2005) (0)
- OC-0049: Genomic profiling of muscle invasive bladder cancer to predict response to chemoradiation therapy (2018) (0)
- Point and counterpoint. Radical cystectomy or multimodality therapy for TCC of the bladder? (1995) (0)
- DRIAMYGIN SENSITIVITY FOLLOWING "ULTRA" LOW TE IRRADIATION OF LEWIS LUNG CARCINOMA IN (1985) (0)
- PSA screening. (1994) (0)
- 536 oral RTOG 9601: SALVAGE RT & ANTI-ANDROGEN THERAPY IN PROSTATE CANCER PATIENTS WITH ELEVATED PSA AFTER SURGERY (2011) (0)
- Radiation Therapy: its Integration with Surgery and Chemotherapy in the Management of Patients with Urological Malignancy (1989) (0)
- 31 A comparison between neoadjuvant and adjuvant androgen withdrawal with radiation in an experimental rodent model (1996) (0)
- Bladder Preservation Therapy for Muscle-Invading Bladder Cancers (MIBC): Long-term Clinical Outcomes from RTOG 8802, 8903, 9506, and 9706 and Molecular Correlates along the VEGF Pathway (2011) (0)
- 141 Thymosin B15 staining predicts for distant failure in patients with prostate cancer who are clinically M0 at presentation (1999) (0)
- A comparative study of surgery vs radioactive iodine-125 implantation in the treatment of pancreatic cancer (1978) (0)
- Intraoperative Radiation for Unresectable Carcinoma of the Pancreas (1984) (0)
- Radiation Therapy for Clinically Localized Prostate Cancer (2016) (0)
- Impact of High DosE rAdioTherapy (HEAT) in Localized Prostate Cancer: An Individual Patient Data (IPD) Meta-Analysis of 15 Randomized Trials. (2021) (0)
- Comparative Effectiveness of Bladder-Preserving Tri-Modality Therapy versus Radical Cystectomy for Muscle-Invasive Bladder Cancer (2018) (0)
- Words of Wisdom. Re: Radical Cystectomy vs. Chemoradiation in T2-4aN0M0 Bladder Cancer: A Case-control Study. (2016) (0)
- Higher suspicion with a lower PSA: Skeletal metastases after radical radiation therapy for localized prostate cancer (1998) (0)
- Genomic Determinants of Response to Trimodality Therapy for Muscle-Invasive Bladder Cancer (2022) (0)
- 2215 : Does Testosterone Influence Radiation-Induced Toxicity In Radiotherapy of the Prostate? A Secondary Analysis of RTOG Protocol 9413 (2006) (0)
- A PHASE MI TRIAL OF TRANSURETHRAL SURGERY COMBINED WITH RADIATION FOLLOWED BY SELECTIVE BLADDER PRESERVATION IN OPERABLE PATIENTS WITH MUSCLE INVADING BLADDER CANCER CONCURRENT CISPLATIN, 5-FLUOROURACIL AND TWICE DAILY (1998) (0)
- Radiation-sensitizing chemotherapy after transurethral resection as an alternative treatment for high-risk T1 bladder cancer (2007) (0)
- Biology and management of bladder cancer. (1991) (0)
- Feasibility of Gene Expression Signature Analysis in Prostate Cancer Biopsy Specimens to Predict Outcomes Following Radiation Therapy (2013) (0)
- Reply from Authors re: Giuseppe Simone, Michele Gallucci. Multimodality Treatment Versus Radical Cystectomy: Bladder Sparing at Cost of Life? Eur Urol 2012;61:712–3: Bladder-Sparing Therapy: The Urologist Doth Protest Too Much, Methinks (2012) (0)
- 459 The treatment of localized prostate cancer by external beam irradiation: Long-term freedom from biochemical recurrence (1995) (0)
- Long-term QOL Outcome after Proton Radiation for Localized Prostate Cancer (2010) (0)
- “Ultra” low dose-rate irradiation: Effects of prolonged exposures on population growth, survival and radiation sensitivity in cultured mammalian cells (1980) (0)
- MP56-14 LONG-TERM RENAL FUNCTION IN PATIENTS UNDERGOING TRIMODAL THERAPY FOR BLADDER CANCER (2023) (0)
- Long-term Results of Early Salvage Versus Adjuvant Postprostatectomy Radiation: A Large Institutional Experience (2015) (0)
- PSA SCREENING. AUTHORS' REPLY (1994) (0)
- Multimodality Management in Primary Urethral Cancer: The Role of Radiation Therapy (2013) (0)
- Mapping patterns of nodal metastases in seminoma: Rethinking radiotherapy fields. (2012) (0)
- Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of Radiation Therapy Oncology Group protocol 9413. (2006) (0)
- Presentation, Treatment, and Outcomes for Bladder Cancer Patients With Nonurothelial Histologies Treated by Radical Cystectomy: Implications for Adjuvant Radiation Therapy (2013) (0)
- Commentary (Shipley): Current Management of Unusual Genitourinary Cancers (1999) (0)
- Bladder-Conserving Therapy for Invasive Bladder Cancer Using Transurethral Surgery, Chemotherapy, and Radiation Therapy with Patient Selection by Initial Treatment Response (1998) (0)
- 1003 Chemotherapy and radiation therapy with selective organ-sparing treatment of invasive bladder cancer (1995) (0)
- OC-0057: Randomized phase 2 trial of radiation with either gemcitabine or 5FU/cisplatin in bladder cancer (2018) (0)
- MP62-14 LONG-TERM RESULTS OF POST-PROSTATECTOMY RADIOTHERAPY: A LARGE INSTITUTIONAL EXPERIENCE (2015) (0)
- Short-Term Adjuvant versus Neoadjuvant Hormone Therapy in Localized Prostate Cancer: A Pooled Individual Patient Analysis of Two Randomized Phase 3 Trials (2020) (0)
- Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy (2022) (0)
- Role of lymphangiography in staging testicular seminoma. (1991) (0)
- Long-term outcomes after bladder-preserving combined-modality therapy for patients with muscle-invasive bladder cancer. (2016) (0)
- Enhanced radiation response of small pulmonary metastases of the lewis lung carcinoma. Abstr. (1975) (0)
- VIV0 AT CLINICALLY-USED "ULTRA" LOW-DOSE-RATES (1983) (0)
- An update of RTOG clinical trials of combined androgen suppression and radiation in localized prostatic carcinoma (1996) (0)
- Factors Associated With Clinical-Pathologic Stage Discrepancy in Bladder Cancer Patients Treated With Radical Cystectomy: Implications for Treatment Selection and Comparative Studies (2012) (0)
- Outcomes and tolerability of selective bladder preservation by combined modality therapy for invasive bladder cancer in elderly patients. (2017) (0)
- [Intraoperative irradiation in non-radical surgery of abdominal neoplasms]. (1982) (0)
- Selective bladder preservation with twice-daily radiation plus 5-flourouracil/cisplatin (FCT) or daily radiation plus gemcitabine (GD) for patients with muscle invasive bladder cancer: Primary results of NRG/RTOG 0712—A randomized phase 2 multicenter trial. (2018) (0)
- Treatment of carcinoma of the urinary bladder (1979) (0)
- Re: The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. (1994) (0)
- Diabetes and mortality in men with locally advanced prostate cancer: analyses of RTOG 92–02 (2008) (0)
- Inverse probability treatment weighting comparison of radical cystectomy to trimodality therapy for cT2-cT4 muscle invasive bladder cancer (2023) (0)
- PSA Bounces After Neoadjuvant Androgen Deprivation and External Beam Radiation: Impact on Definitions of Failure (2006) (0)
- Interstitial Radiation Therapy for Management of Localized Prostate Cancer (1983) (0)
- Late Breaking Abstracts LBA 1 Two Years of AntiAndrogen Treatment Increases Other-Cause Mortality in Men Receiving Early Salvage Radiotherapy : A Secondary Analysis of the NRG Oncology / RTOG 9601 Randomized Phase III Trial (2019) (0)
- Association of Statin Use with Local Control in Patients Treated with Selective Bladder Preservation for Muscle-Invasive Bladder Cancer (2005) (0)
- Bladder Cancer: Invasive IModerated Poster1414 COMPLICATIONS AND LONG-TERM RESULTS OF SALVAGE CYSTECTOMY AFTER FAILED BLADDER-SPARING THERAPY FOR MUSCLE-INVASIVE BLADDER CANCER (2012) (0)
- Integrating chemotherapy and radiotherapy for bladder cancer (2015) (0)
- Title: Bladder Preservation Therapy for Muscle-Invading Bladder Cancers on RTOG 8802, 8903, 9506, and 9706: Vascular endothelial growth factor B over expression predicts for increased distant metastasis and shorter survival (2013) (0)
- Long-term QOL outcome after proton beam monotherapy for localized prostate cancer. (2011) (0)
- Oral Scientific SessionsSubtyping Muscle-Invasive Bladder Cancer to Assess Clinical Response to Trimodality Therapy (2017) (0)
- Treatment Patterns and Outcomes of Nonurothelial Cell Carcinoma of the Bladder: Results From the National Cancer Data Base (2016) (0)
- Phospho-AKT Expression and Prognosis of Locally Advanced Prostate Cancer: A Study Based on RTOG 8610 (2005) (0)
- Propensity matched comparison of radical cystectomy with trimodality therapy for muscle invasive bladder cancer (MIBC): A multi-institutional study (2022) (0)
- Clinical Outcomes of Combined Modality Bladder-Sparing Therapy for Patients With Histologic Variants of Bladder Cancer (2016) (0)
- The Natural History of Nonmuscle-Invasive Bladder Cancer Recurrences After Complete Response to Combined-Modality Organ-Preserving Therapy for Muscle-Invasive Bladder Cancer (2016) (0)
- BOOK REVIEW Comprehensive Textbook of Genitourinary Oncology (2005) (0)
- Bladder carcinoma: The selection of patients for radiation therapy, transurethral or radical surgery and possible chemotherapy (1986) (0)
- Nomogram for Predicting Risk of Cystectomy or Recurrence after Bladder Preserving Trimodality Therapy for Muscle Invasive Bladder Cancer (2011) (0)
- Late GI and GU sequelae in the second decade following high dose conformal radiation to 77.4 Gy with combined photons/protons for T3-4 prostate cancer (2000) (0)
- Prediction of metastatic potential and survival in muscle-invasive bladder carcinoma treated with neoadtubant chemotherapy and radiotherapy with selective bladder preservation (1991) (0)
- MP49-17 CLINICAL OUTCOMES OF PATIENTS WITH HISTOLOGIC VARIANTS OF BLADDER CANCER TREATED WITH TRIMODAL BLADDER-SPARING THERAPY (2016) (0)
- Bowel and bladder toxicity patterns in patients with prostate cancer treated with proton beam versus intensity-modulated radiation therapy. (2012) (0)
- Bladder carcinoma: The selection of patients for radiation therapy (1984) (0)
- Cell kinetic factors predicting local control following radiation therapy for prostate cancancer: An assessment of % s-phase, total proliferative fraction and DNA ploidy (1993) (0)
- 2053 Probability of subsequent failure in men with prostate cancer clinically disease free 10 years after treatment with radiation therapy (1996) (0)
- Impact of lymph node yield at prostatectomy on outcomes in NRG/RTOG 9601. (2022) (0)
- The Impact of Persistently Elevated PSA after Prostatectomy in Men with Recurrent Prostate Cancer in NRG Oncology/RTOG 9601 (2020) (0)
- Renal function in bladder cancer patients after trimodality therapy: Long-term results of a large institutional experience. (2016) (0)
- Less Is More. (2017) (0)
- 1456: Recursive Partitioning Analysis of Predictors of Distant Metastasis for Men with Prostate Cancer Treated with Radiotherapy and Androgen Deprivation on RTOG 9202: The Impact of KI-67 (2004) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With William U. Shipley?
William U. Shipley is affiliated with the following schools:
